Gastroenterology
Latest news
416 articles · 20 / page
Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial
A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highl
THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results
A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight
Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study
A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and g
Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients
A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial ex
Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis
A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcin
MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing crit
Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer
A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.
Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis
A comprehensive study integrating global and individual data reveals that adherence to the Planetary Health Diet Index (PHDI) provides significant protection against metabolic dysfunction-associated steatotic liver disease (MASLD), highligh
The Double-Win Diet: How the Planetary Health Index Protects Your Liver and the Earth
This article explores the groundbreaking link between the Planetary Health Diet Index (PHDI) and reduced risks of metabolic dysfunction-associated steatotic liver disease (MASLD), offering evidence-based insights for personal health and env
Healthy Nordic Diet vs. Anti-Lipogenic High-Fat Diet: Superior Cardiometabolic Outcomes in the NAFLDiet Trial
The NAFLDiet trial reveals that while both anti-lipogenic LCPUFA and Healthy Nordic Diets reduce liver fat, the Nordic diet offers superior benefits for weight loss, glycemic control, and systemic inflammation in patients with type 2 diabet
Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis
This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom’s efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.
Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial
The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transfo
AXL: The Double-Edged Sword in Colorectal Cancer Treatment
Researchers have identified AXL expression as a critical biomarker in colorectal cancer. While it usually signals treatment resistance, a new study reveals that AXL-high tumors with KRAS mutations respond significantly better to immunothera
Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer
The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with
HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation
A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumo
Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity
Researchers have developed ICyM2, a carrier-free nanoaggregate that combines mitochondrial phototherapy with STING activation. This platform effectively remodels the dense pancreatic cancer stroma, triggers immunogenic cell death, and syner
Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer
A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of
Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials
GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentiall
SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD
A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partiall
Neoadjuvant Chemoradiotherapy vs. Surgery with Adjuvant Therapy for ESCC: Five-Year Outcomes Challenge the Universal Standard
A Phase 3 randomized clinical trial finds no significant difference in 5-year overall survival between neoadjuvant chemoradiotherapy and surgery with adjuvant therapy for locally advanced ESCC, emphasizing the need for personalized treatmen
Browse by specialty
Open language-specific specialty feeds and department pages.